With the disappointing effects observed in the early clinical trials for obesity and these theoretical side effects and toxicities, the enthusiasm for developing agents that are exclusive cholecystokinin agonists for obesity has waned, and we are not aware of any active drug development programs continuing to pursue this (12). The gene discussed is CCK; the disease is Obesity.